Ibrutinib for Blood Cancer Treatment

Ibrutinib is revolutionizing the treatment of blood cancers like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As a targeted therapy, it inhibits Bruton’s tyrosine kinase (BTK), essential for cancer cell survival, thereby halting the growth and spread of malignant cells.